A searchable database of
medically documented cases

About the Project

Spontaneous Remission Of A Pulmonary Sclerosing Epithelioid Fibrosarcoma: A Case Report Of A Possible Abscopal Effect

Campos & Amírez, 2024Sarcoma

Campos Ramírez, S. E., Gómez Mateo, M. C., Ruffini Egea, S. E., Monreal Cepero, M. L., Gómez Mugarza, P., Barriendos Sanz, S., & Martinez Trufero, J. (2024). Spontaneous remission of a pulmonary sclerosing epithelioid fibrosarcoma: a case report of a possible abscopal effect. Translational cancer research, 13(5), 2564–2570. https://doi.org/10.21037/tcr-23-2276

View Original Source →

Abstract

BACKGROUND: Spontaneous remission (SR) is defined as the complete or partial disappearance of a diagnosed malignant disease in the absence of known active medical treatment. The role of the immune system is thought to be important, but has not yet been elucidated. On this matter, there are studies that suggest that the abscopal effect (AE), which is defined as the remission of untreated lesions beyond the irradiated area, may be explained by the activation of a systemic immune response against the tumor. Sclerosing epithelioid fibrosarcoma (SEF) is a rare variant of soft tissue sarcoma that is characterized by a slow evolution, with local recurrences and late metastases. The treatment is based on surgery, leaving a minimal role to chemotherapy (ChT) and radiotherapy (RT) for metastatic unresectable disease, and no cases of SR have been reported in the literature so far. CASE DESCRIPTION: We present the case of a patient with a lung metastatic recurrence of SEF, diagnosed and treated with surgery 8 years before. After progression to pazopanib and other ChT drugs, because of the chest pain associated with a pleural mass invading the second costal arch, the patient received antalgic local RT treatment. Months later, and without any further treatment, a partial remission of all the tumoral lesions was presented, and she is alive 25 years after the first diagnosis. CONCLUSIONS: As far as reported in the literature, this is the first case of SR in SEF. Among the possible causes of this SR, we think that the most plausible is that palliative treatment with RT of the pleural mass induced an AE, leading to a reduction of all tumoral lesions, even those outside the irradiated region.

Case Details

Disease Location

Lung

Personal Characteristics

58-year-old woman

Clinical Characteristics

Had an excision surgery of a 7-cm pleural mass that had been discovered during the perioperative assessment for anal fistula surgery. The initial diagnosis was a low-grade fibrotic pleural neoplasm. After surgery, the patient was followed by periodical chest computed tomography (CT). A second surgery was performed in april 2012 for a pulmonary nodule of 9 mm in the lingula, with a pathological report of a fusocelular proliferation suggesting solitary fibrous tumor/hemangiopericytoma. A third surgical intervention was performed in july 2016. A total of 7 pulmonary nodules were resected. The final pathologic report informed of a low-grade fusocelular and epithelioid sarcoma, with diffuse positive immunostaining for muc4. The diagnosis was consistent with sclerosing epithelioid fibrosarcoma (sef). She received six cycles of doxorubicin with stabilization of tumoral lesions. Then she started with pazopanib at an initial dose of 800 mg/day, which was later reduced to 600 mg/day due to diarrhea and palmo-plantar syndrome. Four months later, a second line with gemcitabine and dacarbazine was tried, receiving a total of nine cycles. Due to increasing pain in the right hemithorax and the lack of any other targeted therapy, the patient received rt in that area, a total of 5 sessions of 4 gy (total dose of 20 gy). The patient got the fourth dose of the covid-19 vaccine 1 year before starting radiotherapy

Remission Characteristics

At first, one month after rt, it increased in size to be followed by a reduction of the mass (9 months after). This reduction was observed in all the metastatic lesions, even in those that were not irradiated.

Treatment & Mechanisms

Proposed Remission Mechanisms

Radiotherapy led to immune system activation within the micro-tumoral environment.

Clinical Treatment

Biopsy, chemotherapy (doxorubicin, pazopanib, gemcitabine, dacarbazine), radiotherapy, covid-19 vaccine